Which has better earnings & valuation, HAE or DXCM?

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 4.18 $97.31M $2.23 54.91 DexCom $4.66B 6.39 $836.30M $2.55 31.34

Is HAE or DXCM more profitable?

DexCom has a net margin of 19.42% compared to Haemonetics' net margin of 7.52%. DexCom's return on equity of 37.77% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.52% 27.42% 9.77% DexCom 19.42% 37.77% 15.98%

Does the media prefer HAE or DXCM?

In the previous week, Haemonetics had 25 more articles in the media than DexCom. MarketBeat recorded 31 mentions for Haemonetics and 6 mentions for DexCom. DexCom's average media sentiment score of 1.03 beat Haemonetics' score of 0.66 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 7 Very Positive mention(s) 7 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HQY or HAE?

In the previous week, Haemonetics had 28 more articles in the media than HealthEquity. MarketBeat recorded 31 mentions for Haemonetics and 3 mentions for HealthEquity. Haemonetics' average media sentiment score of 0.66 beat HealthEquity's score of 0.59 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 7 Very Positive mention(s) 7 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, LNTH or HAE?

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.56B 4.25 $233.56M $4.06 25.03 Haemonetics $1.33B 4.18 $97.31M $2.23 54.91

Is LNTH or HAE more profitable?

Lantheus has a net margin of 17.28% compared to Haemonetics' net margin of 7.52%. Lantheus' return on equity of 29.26% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.28% 29.26% 15.40% Haemonetics 7.52% 27.42% 9.77%

Does the media favor LNTH or HAE?

In the previous week, Haemonetics had 20 more articles in the media than Lantheus. MarketBeat recorded 31 mentions for Haemonetics and 11 mentions for Lantheus. Lantheus' average media sentiment score of 0.67 beat Haemonetics' score of 0.66 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 7 Very Positive mention(s) 7 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, PODD or HAE?

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.79 $247.10M $6.14 24.11 Haemonetics $1.33B 4.18 $97.31M $2.23 54.91

Is PODD or HAE more profitable?

Insulet has a net margin of 13.44% compared to Haemonetics' net margin of 7.52%. Insulet's return on equity of 31.76% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Insulet 13.44% 31.76% 14.48% Haemonetics 7.52% 27.42% 9.77%

Does the media refer more to PODD or HAE?

In the previous week, Insulet had 22 more articles in the media than Haemonetics. MarketBeat recorded 53 mentions for Insulet and 31 mentions for Haemonetics. Insulet's average media sentiment score of 0.82 beat Haemonetics' score of 0.66 indicating that Insulet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 17 Very Positive mention(s) 9 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 7 Very Positive mention(s) 7 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, HAE or QTRX?

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 4.18 $97.31M $2.23 54.91 Quanterix $138.90M 1.12 -$107.15M -$2.63 N/A

Is HAE or QTRX more profitable?

Haemonetics has a net margin of 7.52% compared to Quanterix's net margin of -75.05%. Haemonetics' return on equity of 27.42% beat Quanterix's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.52% 27.42% 9.77% Quanterix -75.05% -29.02% -21.41%

Does the media prefer HAE or QTRX?

In the previous week, Haemonetics had 17 more articles in the media than Quanterix. MarketBeat recorded 31 mentions for Haemonetics and 14 mentions for Quanterix. Haemonetics' average media sentiment score of 0.66 beat Quanterix's score of 0.04 indicating that Haemonetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 7 Very Positive mention(s) 7 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quanterix 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Haemonetics (HAE) Competitors

$120.72 -1.65 (-1.34%)

Closing price 03:59 PM Eastern

Extended Trading

$121.60 +0.89 (+0.74%)

As of 07:52 PM Eastern

Compare

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

Should you buy Haemonetics stock or one of its competitors? Haemonetics's main competitors and comparable companies include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), and Quanterix (QTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Haemonetics compare to DexCom?

Haemonetics (NYSE:HAE) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Haemonetics presently has a consensus price target of $126.38, indicating a potential upside of 3.21%. DexCom has a consensus price target of $95.50, indicating a potential upside of 19.49%. Given DexCom's stronger consensus rating and higher possible upside, analysts plainly believe DexCom is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
DexCom	0 Sell rating(s)	2 Hold rating(s)	24 Buy rating(s)	2 Strong Buy rating(s)	3.00

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	4.18	$97.31M	$2.23	54.91
DexCom	$4.66B	6.39	$836.30M	$2.55	31.34

Haemonetics has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DexCom has a net margin of 19.42% compared to Haemonetics' net margin of 7.52%. DexCom's return on equity of 37.77% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.52%	27.42%	9.77%
DexCom	19.42%	37.77%	15.98%

In the previous week, Haemonetics had 25 more articles in the media than DexCom. MarketBeat recorded 31 mentions for Haemonetics and 6 mentions for DexCom. DexCom's average media sentiment score of 1.03 beat Haemonetics' score of 0.66 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	7 Very Positive mention(s)	7 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Haemonetics on 14 of the 17 factors compared between the two stocks.

How does Haemonetics compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and Haemonetics (NYSE:HAE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

HealthEquity currently has a consensus price target of $113.53, indicating a potential upside of 9.65%. Haemonetics has a consensus price target of $126.38, indicating a potential upside of 3.21%. Given HealthEquity's stronger consensus rating and higher probable upside, research analysts clearly believe HealthEquity is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Haemonetics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82

HealthEquity has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

In the previous week, Haemonetics had 28 more articles in the media than HealthEquity. MarketBeat recorded 31 mentions for Haemonetics and 3 mentions for HealthEquity. Haemonetics' average media sentiment score of 0.66 beat HealthEquity's score of 0.59 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	7 Very Positive mention(s)	7 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HealthEquity has a net margin of 17.36% compared to Haemonetics' net margin of 7.52%. Haemonetics' return on equity of 27.42% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	17.36%	15.33%	9.51%
Haemonetics	7.52%	27.42%	9.77%

HealthEquity has higher earnings, but lower revenue than Haemonetics. HealthEquity is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.31B	6.52	$215.20M	$2.77	37.38
Haemonetics	$1.33B	4.18	$97.31M	$2.23	54.91

99.6% of HealthEquity shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.6% of HealthEquity shares are held by company insiders. Comparatively, 2.1% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

HealthEquity and Haemonetics tied by winning 8 of the 16 factors compared between the two stocks.

How does Haemonetics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Haemonetics (NYSE:HAE) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.56B	4.25	$233.56M	$4.06	25.03
Haemonetics	$1.33B	4.18	$97.31M	$2.23	54.91

Lantheus has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

In the previous week, Haemonetics had 20 more articles in the media than Lantheus. MarketBeat recorded 31 mentions for Haemonetics and 11 mentions for Lantheus. Lantheus' average media sentiment score of 0.67 beat Haemonetics' score of 0.66 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	7 Very Positive mention(s)	7 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 17.28% compared to Haemonetics' net margin of 7.52%. Lantheus' return on equity of 29.26% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.28%	29.26%	15.40%
Haemonetics	7.52%	27.42%	9.77%

Lantheus presently has a consensus target price of $107.44, indicating a potential upside of 5.73%. Haemonetics has a consensus target price of $126.38, indicating a potential upside of 3.21%. Given Lantheus' higher possible upside, research analysts clearly believe Lantheus is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21
Haemonetics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82

99.1% of Lantheus shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 2.1% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Lantheus beats Haemonetics on 10 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Insulet?

Insulet (NASDAQ:PODD) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

In the previous week, Insulet had 22 more articles in the media than Haemonetics. MarketBeat recorded 53 mentions for Insulet and 31 mentions for Haemonetics. Insulet's average media sentiment score of 0.82 beat Haemonetics' score of 0.66 indicating that Insulet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	17 Very Positive mention(s)	9 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	7 Very Positive mention(s)	7 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Haemonetics shares are owned by institutional investors. 0.4% of Insulet shares are owned by insiders. Comparatively, 2.1% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Insulet presently has a consensus price target of $185.67, indicating a potential upside of 25.40%. Haemonetics has a consensus price target of $126.38, indicating a potential upside of 3.21%. Given Insulet's higher probable upside, equities analysts clearly believe Insulet is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.44
Haemonetics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82

Insulet has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.79	$247.10M	$6.14	24.11
Haemonetics	$1.33B	4.18	$97.31M	$2.23	54.91

Insulet has a net margin of 13.44% compared to Haemonetics' net margin of 7.52%. Insulet's return on equity of 31.76% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	13.44%	31.76%	14.48%
Haemonetics	7.52%	27.42%	9.77%

Summary

Insulet beats Haemonetics on 12 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Quanterix?

Haemonetics (NYSE:HAE) and Quanterix (NASDAQ:QTRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Haemonetics has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by insiders. Comparatively, 1.5% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	4.18	$97.31M	$2.23	54.91
Quanterix	$138.90M	1.12	-$107.15M	-$2.63	N/A

In the previous week, Haemonetics had 17 more articles in the media than Quanterix. MarketBeat recorded 31 mentions for Haemonetics and 14 mentions for Quanterix. Haemonetics' average media sentiment score of 0.66 beat Quanterix's score of 0.04 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	7 Very Positive mention(s)	7 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quanterix	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Haemonetics currently has a consensus price target of $126.38, indicating a potential upside of 3.21%. Quanterix has a consensus price target of $3.50, indicating a potential upside of 6.71%. Given Quanterix's higher probable upside, analysts plainly believe Quanterix is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Haemonetics has a net margin of 7.52% compared to Quanterix's net margin of -75.05%. Haemonetics' return on equity of 27.42% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.52%	27.42%	9.77%
Quanterix	-75.05%	-29.02%	-21.41%

Summary

Haemonetics beats Quanterix on 14 of the 16 factors compared between the two stocks.

Get Haemonetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HAE vs. The Competition

Export

Metric	Haemonetics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$5.57B	$6.05B	$7.89B	$23.43B
Dividend Yield	N/A	1.68%	2.45%	3.75%
P/E Ratio	24.04	35.77	34.35	25.09
Price / Sales	4.12	5.14	8.79	3.24
Price / Cash	16.14	24.03	22.08	15.86
Price / Book	6.12	4.38	4.45	3.73
Net Income	$97.31M	$142.48M	$3.50B	$1.08B
7 Day Performance	-5.25%	-1.83%	-0.97%	-0.63%
1 Month Performance	1.56%	-0.86%	-4.07%	1.06%
1 Year Performance	68.25%	2.27%	2.04%	6.73%

Haemonetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HAE Haemonetics	1.9119 of 5 stars	$120.72 -1.3%	$126.38 +4.7%	+73.5%	$5.57B	$1.33B	24.04	3,009	Earnings Report
DXCM DexCom	3.9317 of 5 stars	$84.76 +3.0%	$95.50 +12.7%	+45.7%	$31.05B	$5.10B	33.24	11,000	Positive News
HQY HealthEquity	3.4812 of 5 stars	$103.67 +1.2%	$113.53 +9.5%	+3.7%	$8.38B	$1.31B	37.43	2,814
LNTH Lantheus	2.8975 of 5 stars	$100.31 -0.1%	$107.44 +7.1%	+100.5%	$6.54B	$1.54B	20.10	1,193	Earnings Report
PODD Insulet	4.3643 of 5 stars	$153.61 +2.6%	$186.68 +21.5%	-53.8%	$10.38B	$3.05B	28.71	5,400	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HAE) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Summary

How does Haemonetics compare to HealthEquity?

Summary

How does Haemonetics compare to Lantheus?

Summary

How does Haemonetics compare to Insulet?

Summary

How does Haemonetics compare to Quanterix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Do analysts prefer HAE or DXCM?

Which has better earnings & valuation, HAE or DXCM?

Which has more risk & volatility, HAE or DXCM?

Do institutionals & insiders believe in HAE or DXCM?

Is HAE or DXCM more profitable?

Does the media prefer HAE or DXCM?

Summary

How does Haemonetics compare to HealthEquity?

Do analysts recommend HQY or HAE?

Which has more risk & volatility, HQY or HAE?

Does the media favor HQY or HAE?

Is HQY or HAE more profitable?

Which has stronger earnings & valuation, HQY or HAE?

Do insiders and institutionals believe in HQY or HAE?

Summary

How does Haemonetics compare to Lantheus?

Which has better valuation & earnings, LNTH or HAE?

Which has more risk and volatility, LNTH or HAE?

Does the media favor LNTH or HAE?

Is LNTH or HAE more profitable?

Do analysts recommend LNTH or HAE?

Do institutionals & insiders believe in LNTH or HAE?

Summary

How does Haemonetics compare to Insulet?

Does the media refer more to PODD or HAE?

Do insiders & institutionals have more ownership in PODD or HAE?

Do analysts rate PODD or HAE?

Which has more volatility & risk, PODD or HAE?

Which has preferable valuation & earnings, PODD or HAE?

Is PODD or HAE more profitable?

Summary

How does Haemonetics compare to Quanterix?

Which has more volatility & risk, HAE or QTRX?

Do institutionals & insiders believe in HAE or QTRX?

Which has higher valuation and earnings, HAE or QTRX?

Does the media prefer HAE or QTRX?

Do analysts prefer HAE or QTRX?

Is HAE or QTRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools